EMN 2021 | DART4MM: daratumumab in myeloma patients with VGPR to first-line therapy
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, outlines interim analysis results from the DART4MM study (NCT03992170) investigating daratumumab for measurable residual disease (MRD) eradication in patients with multiple myeloma who achieved a very good partial response (VGPR) to first-line therapy. Next generation flow (NGF) was used for MRD detection. Out of 26 patients who completed six months of therapy, 12 achieved MRD negativity. 12/23 patients previously treated with autologous stem cell transplantation were MRD-negative after six months of daratumumab therapy. Overall, the initial results have shown promising efficacy in patients who achieved a VGPR to first-line therapy. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Alessandro Gozzetti, MD, PhD, has received research funding from Janssen and Cilag Spa.
